Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk

Exclusion Criteria

• •1. Prostate cancer of histology other than adenocarcinoma,
• •2. Patient diagnosed with N1 during imaging or pN1,
• •3. serum PSA level\> 100 ng / ml,
• •4. IPSS score ≥ 12 or alpha blocker treatment,
• •5. Prostate volume estimated on MRI or ultrasound\> 60 cc
• •6. History of cancer in the 5 years prior to entry into the trial,
• •7. History of trans-urethral resection of prostate less than 6 months old,
• •8. History of rectal surgery,
• •9. History of pelvic irradiation,
• •10. Patient with severe hypertension not controlled by appropriate treatment,
• •11. Contraindication to pelvic irradiation,
• •* Prostate volume\> 60cc
• •* Urine flow measurement with max flow \<12 mL / s
• •* Or curative anticoagulant treatment
• •* Or contraindication to general anesthesia
• •13. Patient treated with antineoplastic or drug may include methotrexate,
• •14. Hormone therapy started\> 90 days before the first irradiation,
• •15. Patient on immunosuppressant therapy
• •16. Contraindication to agonists or antagonists of LHRH,
• •17. Bilateral hip prosthesis,
• •18. Patient already included in another therapeutic trial with an experimental molecule,
• •19. Patient unable to cooperate during treatment,
• •20. Persons deprived of their liberty or guardianship,
• •21. Inability to undergo medical follow-up of the test.